Literature DB >> 29198864

Small molecule inhibitors of anthrax edema factor.

Guan-Sheng Jiao1, Seongjin Kim1, Mahtab Moayeri2, April Thai1, Lynne Cregar-Hernandez1, Linda McKasson1, Sean O'Malley1, Stephen H Leppla2, Alan T Johnson3.   

Abstract

Anthrax is a highly lethal disease caused by the Gram-(+) bacteria Bacillus anthracis. Edema toxin (ET) is a major contributor to the pathogenesis of disease in humans exposed to B. anthracis. ET is a bipartite toxin composed of two proteins secreted by the vegetative bacteria, edema factor (EF) and protective antigen (PA). Our work towards identifying a small molecule inhibitor of anthrax edema factor is the subject of this letter. First we demonstrate that the small molecule probe 5'-Fluorosulfonylbenzoyl 5'-adenosine (FSBA) reacts irreversibly with EF and blocks enzymatic activity. We then show that the adenosine portion of FSBA can be replaced to provide more drug-like molecules which are up to 1000-fold more potent against EF relative to FSBA, display low cross reactivity when tested against a panel of kinases, and are nanomolar inhibitors of EF in a cell-based assay of cAMP production.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anthrax; Covalent inhibitor; Edema factor

Mesh:

Substances:

Year:  2017        PMID: 29198864      PMCID: PMC5875723          DOI: 10.1016/j.bmcl.2017.11.040

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  32 in total

Review 1.  Anthrax lethal and edema toxins in anthrax pathogenesis.

Authors:  Shihui Liu; Mahtab Moayeri; Stephen H Leppla
Journal:  Trends Microbiol       Date:  2014-03-27       Impact factor: 17.079

Review 2.  Anthrax toxins: a weapon to systematically dismantle the host immune defenses.

Authors:  Jean-Nicolas Tournier; Silvia Rossi Paccani; Anne Quesnel-Hellmann; Cosima T Baldari
Journal:  Mol Aspects Med       Date:  2009-06-26

3.  Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate.

Authors:  Neil P Grimster; Stephen Connelly; Aleksandra Baranczak; Jiajia Dong; Larissa B Krasnova; K Barry Sharpless; Evan T Powers; Ian A Wilson; Jeffery W Kelly
Journal:  J Am Chem Soc       Date:  2013-02-14       Impact factor: 15.419

4.  High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.

Authors:  F Wohnsland; B Faller
Journal:  J Med Chem       Date:  2001-03-15       Impact factor: 7.446

5.  Hijacking multivesicular bodies enables long-term and exosome-mediated long-distance action of anthrax toxin.

Authors:  Laurence Abrami; Lucia Brandi; Mahtab Moayeri; Michael J Brown; Bryan A Krantz; Stephen H Leppla; F Gisou van der Goot
Journal:  Cell Rep       Date:  2013-11-14       Impact factor: 9.423

Review 6.  Designing Irreversible Inhibitors--Worth the Effort?

Authors:  Concepción González-Bello
Journal:  ChemMedChem       Date:  2015-11-23       Impact factor: 3.466

7.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

8.  Ascertaining the suitability of aryl sulfonyl fluorides for [18F]radiochemistry applications: a systematic investigation using microfluidics.

Authors:  Lidia Matesic; Naomi A Wyatt; Benjamin H Fraser; Maxine P Roberts; Tien Q Pham; Ivan Greguric
Journal:  J Org Chem       Date:  2013-11-07       Impact factor: 4.354

9.  Hemodynamic effects of anthrax toxins in the rabbit model and the cardiac pathology induced by lethal toxin.

Authors:  William S Lawrence; Jeffrey R Marshall; Diana L Zavala; Lori E Weaver; Wallace B Baze; Scott T Moen; Elbert B Whorton; Randy L Gourley; Johnny W Peterson
Journal:  Toxins (Basel)       Date:  2011-06-23       Impact factor: 4.546

10.  Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.

Authors:  J A Jernigan; D S Stephens; D A Ashford; C Omenaca; M S Topiel; M Galbraith; M Tapper; T L Fisk; S Zaki; T Popovic; R F Meyer; C P Quinn; S A Harper; S K Fridkin; J J Sejvar; C W Shepard; M McConnell; J Guarner; W J Shieh; J M Malecki; J L Gerberding; J M Hughes; B A Perkins
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

View more
  2 in total

1.  Acyclic nucleoside phosphonates with 2-aminothiazole base as inhibitors of bacterial and mammalian adenylate cyclases.

Authors:  Petra Břehová; Ema Chaloupecká; Michal Česnek; Jan Skácel; Martin Dračínský; Eva Tloušťová; Helena Mertlíková-Kaiserová; Monica P Soto-Velasquez; Val J Watts; Zlatko Janeba
Journal:  Eur J Med Chem       Date:  2021-05-28       Impact factor: 7.088

Review 2.  Structural Biology and Molecular Modeling to Analyze the Entry of Bacterial Toxins and Virulence Factors into Host Cells.

Authors:  Irène Pitard; Thérèse E Malliavin
Journal:  Toxins (Basel)       Date:  2019-06-24       Impact factor: 4.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.